Enter your keyword

Efficiently Creating Value with Innovative Science

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mateon Provides Update on OT-101
AGOURA HILLS, Calif. , June 01, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc.  (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Fatih M. Uckun , Vuong Trieu .  Targeting Transforming Growth Factor-beta for Treatment of COVID-19-associated
View HTML
Toggle Summary FDA Grants Pediatric Disease Designation for Mateon’s CA4P
Treatment of stage IIB–IV melanoma due to genetic mutations that disproportionately affect pediatric patients AGOURA HILLS, Calif. , May 05, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today that the US Food and Drug Administration (FDA) granted Rare Pediatric Disease
View HTML
Toggle Summary Mateon Provides Update on its R&D Effort Against COVID-19
AGOURA HILLS, Calif. , April 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) report several peer-reviewed publications derived from its R&D effort against COVID-19. Published April 24 th , is a special report in the biomedical journal Annals of Pulmonary and Critical Care
View HTML
Toggle Summary Mateon Announces the Filing of an IND with US FDA to Evaluate its Antisense Drug Candidate OT-101 in COVID-19 patients
AGOURA HILLS, Calif. , April 27, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to study its investigational drug, OT-101, for the treatment of COVID-19
View HTML
Toggle Summary Mateon Expands its COVID-19 Therapeutic Program to include Artemisinin
In vitro data generated by the company and its collaborators supports the ability of artemisinin, an anti-malarial drug, to inhibit SARS-CoV-2 which can lead to COVID-19 Artemisinin complements OT-101 which continues to demonstrate potent activity against SARS-CoV-2 and expands the company’s
View HTML
Toggle Summary Mateon Achieves Milestone in its Development of OT-101, a Phase 3 Clinical Drug Candidate, Against COVID-19
OT-101 - a TGF- β 2 antisense - has demonstrated potent antiviral activity against COVID-19   OT-101 is part of the Company’s proprietary platform for rapid antiviral response to COVID-19 and future viral epidemics AGOURA HILLS, Calif. , April 06, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
View HTML
Toggle Summary MATEON THERAPEUTICS TEAM PUBLISHES A NEW PEER-REVIEWED ONCOLOGY ARTICLE ON THE POSITIVE CLINICAL STUDY RESULTS FOR OT-101 AGAINST RECALCITRANT RESISTANT ANAPLASTIC ASTROCYTOMA – A RARE FORM OF MALIGNANT BRAIN TUMOR
AGOURA HILLS, Calif. , April 02, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) today announced the publication of a peer-reviewed research article co-authored by Fatih Uckun MD PhD, Sanjive Qazi PhD, and Vuong Trieu , PhD in the oncology journal Cancer Reports and Reviews.
View HTML
Toggle Summary Mateon Report Positive Results for Multiple COVID-19 Drug Candidates
OT-101 and two additional candidates demonstrated viral inhibition activity against coronavirus AGOURA HILLS, Calif. , March 25, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) dedicated to the development of OT-101, a TGF-Beta antisense drug candidate, today provided an
View HTML
Toggle Summary Mateon Partners With Meridian IT To Fast Track Drug Manufacturing Using Artificial Intelligence For Coronaviruses, Including COVID-19
AGOURA HILLS, Calif. and DEERFIELD, Ill. , March 19, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB:MATN) (“Mateon”) announced today their expanded focus on artificial intelligence (AI) enabled EdgePoint projects by expanding their partnership with Meridian IT, a leading technology
View HTML
Toggle Summary Mateon to Develop its OT-101, a Phase 3 Clinical Drug Candidate, Initially Against COVID-19
OT-101- a TGF- β 2 inhibitor - has demonstrated potent antiviral activity against coronavirus   OT-101 - an RNA therapeutic - is part of the Company’s proprietary platform for rapid antiviral response AGOURA HILLS, Calif. , March 18, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc.
View HTML